{"id":"calcifediol","rwe":[{"pmid":"41846928","year":"2026","title":"Vitamin D(3) as an immunomodulatory agent: molecular mechanisms, clinical translation, and precision therapeutic strategies.","finding":"","journal":"Frontiers in immunology","studyType":"Clinical Study"},{"pmid":"41811220","year":"2026","title":"Structure-Guided Co-Evolution of Fungal Unspecific Peroxygenase for Improved VD(3) C25-Hydroxylation by Substrate-Binding Pocket Engineering.","finding":"","journal":"Journal of agricultural and food chemistry","studyType":"Clinical Study"},{"pmid":"41695203","year":"2024","title":"Quantification of 25-hydroxyvitamin D (3) in dried blood spots as compared to plasma among Indian adults.","finding":"","journal":"F1000Research","studyType":"Clinical Study"},{"pmid":"41608747","year":"2025","title":"Increase in testosterone and cortisol one week after repeated exercise in a cold environment.","finding":"","journal":"Frontiers in physiology","studyType":"Clinical Study"},{"pmid":"41556264","year":"2026","title":"Synergistic Tuning of Conformational Dynamics, Electron Tunneling, and Substrate Positioning Enhances Electron Transfer in a P450 Chimera for Calcifediol Biosynthesis.","finding":"","journal":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","studyType":"Clinical Study"}],"_fda":{"id":"ab6d1f99-2dfe-4392-9fd8-cf0ffcec63ee","risks":["Risk Summary There are no human data with calcifediol use in pregnant women to identify a drug-associated risk for major birth defects, miscarriage or adverse maternal or fetal outcomes. There are risks to the mother and fetus associated with chronic kidney disease in pregnancy (see Clinical Considerations ) . In animal reproduction studies, calcifediol increased skeletal and soft tissue malformation when rabbits were given once daily oral doses representing ≥8 times the human dose of 60 mcg/day, based on body surface area (mg/m 2 ), during the period of organogenesis. No adverse developmental effects were observed in rats given up to 10 times the human dose, based on body surface area (mg/m 2 ), during organogenesis. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.","Risk Summary There is no information available on the presence of calcifediol in human milk, the effects of the drug on the breastfed infant, or the effects of the drug on milk production. Infants potentially exposed to calcifediol through breast milk should be monitored for signs and symptoms of hypercalcemia (see Clinical Considerations ) . The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for RAYALDEE and any potential adverse effects on the breastfed child from RAYALDEE or from the underlying maternal condition."],"set_id":"6a95effd-32a5-46b6-a30e-7f4f9bf8cc77","openfda":{"upc":["0370301100113"],"unii":["P6YZ13C99Q"],"route":["ORAL"],"rxcui":["1855066","1855072"],"spl_id":["ab6d1f99-2dfe-4392-9fd8-cf0ffcec63ee"],"brand_name":["Rayaldee"],"spl_set_id":["6a95effd-32a5-46b6-a30e-7f4f9bf8cc77"],"package_ndc":["70301-1001-1","70301-1001-2","70301-1001-3","70301-1002-1","70301-1002-2","70301-1002-3"],"product_ndc":["70301-1001","70301-1002"],"generic_name":["CALCIFEDIOL"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["CALCIFEDIOL"],"manufacturer_name":["OPKO Pharmaceuticals LLC"],"application_number":["NDA208010"],"is_original_packager":[true]},"version":"10","pregnancy":["8.1 Pregnancy Risk Summary There are no human data with calcifediol use in pregnant women to identify a drug-associated risk for major birth defects, miscarriage or adverse maternal or fetal outcomes. There are risks to the mother and fetus associated with chronic kidney disease in pregnancy (see Clinical Considerations ) . In animal reproduction studies, calcifediol increased skeletal and soft tissue malformation when rabbits were given once daily oral doses representing ≥8 times the human dose of 60 mcg/day, based on body surface area (mg/m 2 ), during the period of organogenesis. No adverse developmental effects were observed in rats given up to 10 times the human dose, based on body surface area (mg/m 2 ), during organogenesis. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. Clinical Considerations Disease-associated maternal and/or embryo/fetal risk Chronic kidney disease in pregnancy increases the maternal risk for hypertension, miscarriage, preterm labor, and preeclampsia. Chronic kidney disease increases the fetal risk for intrauterine growth restriction (IUGR), prematurity, polyhydramnios, still birth, and low birth weight. Data Animal Data Calcifediol was given orally to pregnant rats and rabbits during the period of organogenesis (in rats, from gestation day [GD] 6 to 15; in rabbits, from GD 6 to 18). Rats were given 0, 12, 40, 60 mcg/kg/day; and rabbits were given 0, 5, 25, 50 mcg/kg/day, representing up to 10 and 16 times, respectively, a human dose of 60 mcg/day, based on body surface area (mg/m 2 ). In rats, no adverse developmental effects were observed at calcifediol doses up to 60 mcg/kg/day. In rabbits, increased incidences of domed skull, enlarged atrium of the heart, and dilatation of pulmonary artery, were observed at doses of 25 and 50 mcg/kg/day (representing 8 and 16 times the human dose of 60 mcg/day, respectively, based on body surface area (mg/m 2 ). Rats were given calcifediol during the pre/postnatal period (GD 15 to weaning). No adverse effects on gestation, parturition, lactation or survival of offspring were observed at calcifediol doses up to 60 mcg/kg/day."],"overdosage":["10 OVERDOSAGE Excessive administration of RAYALDEE can cause hypercalciuria, hypercalcemia, hyperphosphatemia, or oversuppression of intact PTH. Common symptoms of vitamin D overdosage may include constipation, decreased appetite, dehydration, fatigue, irritability, muscle weakness, or vomiting. Treatment of acute accidental overdosage with RAYALDEE should consist of general supportive measures. If the overdosage is discovered within a short time, induce emesis or perform gastric lavage to prevent further absorption. Obtain serial serum and urine calcium measurements, and assess any electrocardiographic abnormalities due to hypercalcemia. Discontinue supplemental calcium. Treat with standard medical care if persistent and markedly elevated serum calcium levels occur. Calcifediol is not significantly removed by dialysis."],"description":["11 DESCRIPTION Calcifediol, USP, the active ingredient in RAYALDEE, is synthetically manufactured as calcifediol monohydrate. Calcifediol is also known as calcidiol, 25-hydroxycholecalciferol or 25-hydroxyvitamin D 3 . Calcifediol monohydrate is a white crystalline powder, has a calculated molecular weight of 418.65 and is soluble in alcohol and fatty oils but practically insoluble in water. Chemically, calcifediol monohydrate is (3β,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-3,25-diol monohydrate and its structural formula is: RAYALDEE is formulated as extended-release capsules containing 30 mcg of calcifediol. RAYALDEE is available as soft capsules or two-piece banded hard capsules containing 30 mcg of calcifediol for oral administration. Each capsule contains the following excipients: butylated hydroxytoluene, dehydrated alcohol, hypromellose, lauroyl polyoxylglycerides, mineral oil, monoglycerides and diglycerides, and paraffin. The soft capsule shells contain carrageenan, FD&C Blue #1, modified starch, purified water, sodium phosphate dibasic, sorbitol sorbitan solution, and titanium dioxide. Medium chain triglyceride (fractionated coconut) oil is used as a lubricant during manufacture, and trace amounts may be present in the final formulation. The hard capsule shells contain gellan gum, hypromellose, and titanium dioxide. calcifediol Chemical Structure"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING RAYALDEE is supplied as 30 mcg calcifediol in blue, oval extended-release soft capsules, imprinted O: Bottles of 30 [ NDC 70301-1001-1 ] Bottles of 60 [ NDC 70301-1001-2 ] RAYALDEE is also supplied as 30 mcg calcifediol in white extended-release two-piece banded hard capsules, imprinted O on the cap and 30 on the body: Bottles of 30 [ NDC 70301-1002-1 ] Bottles of 60 [ NDC 70301-1002-2 ] Store at 20 to 25°C (68 to 77°F); excursions permitted to 15 to 30°C (59 to 86°F) [ see USP Controlled Room Temperature ]."],"geriatric_use":["8.5 Geriatric Use Of the total number of subjects in phase 3 placebo-controlled clinical studies of RAYALDEE, 63% were ≥65 years of age and 22% were ≥75 years of age. No overall differences in the safety or efficacy of RAYALDEE were observed between subjects older than 65 years and younger subjects."],"pediatric_use":["8.4 Pediatric Use The safety and efficacy of RAYALDEE have not been established in pediatric patients."],"effective_time":"20240119","clinical_studies":["14 CLINICAL STUDIES The efficacy and safety of RAYALDEE were evaluated in two identical multicenter, randomized, placebo-controlled, double-blind trials in patients with secondary hyperparathyroidism, stage 3 or 4 chronic kidney disease and serum total 25-hydroxyvitamin D levels between 10 and 30 ng/mL. Subjects were stratified by chronic kidney disease stage and randomized in a 2:1 ratio to receive RAYALDEE or a matching placebo at bedtime over 26 weeks. The dose of RAYALDEE was 30 mcg once daily for the first 12 weeks and either 30 or 60 mcg once daily for the last 14 weeks. The dose was increased to 60 mcg at the start of week 13 if the plasma intact PTH level was greater than 70 pg/mL, the serum 25-hydroxyvitamin D level was less than 65 ng/mL and the serum calcium level was less than 9.8 mg/dL. A total of 213 subjects were randomized in one trial (72 received placebo and 141 received RAYALDEE), and 216 subjects were randomized in the second trial (72 received placebo and 144 received RAYALDEE). The subjects’ mean age was 66 years (range 25-85), 50% were male, 65% White, 32% African-American or Black and 3% Other. At baseline, subjects had secondary hyperparathyroidism, and stage 3 (52%) or stage 4 (48%) chronic kidney disease without macroalbuminuria. The most common causes of chronic kidney disease were diabetes and hypertension and the mean estimated GFR was 31 mL/min/1.73m 2 . Mean baseline intact PTH was 130 pg/mL for subjects with stage 3 disease (n=222) and 166 pg/mL for subjects with stage 4 disease (n=207). Mean serum calcium was 9.2 mg/dL, mean serum phosphorus was 3.7 mg/dL and mean serum 25-hydroxyvitamin D was 20 ng/mL. Of the 429 subjects randomized, 354 (83%) completed the studies. The primary analysis compared the proportion of individuals who experienced an at least 30% reduction in plasma intact PTH from baseline to end of trial (average of weeks 20, 22, 24 and 26). A larger proportion of patients randomized to RAYALDEE experienced an at least 30% reduction in plasma intact PTH from baseline compared to placebo in both trials [33% versus 8% in the first trial (P<0.001) and 34% versus 7% in the second trial (P<0.001)]. A description of mean (SE) percent change in plasma intact PTH from baseline across study visits in the two trials combined is shown in Figure 1 . Serum total 25-hydroxyvitamin D levels increased to at least 30 ng/mL in 80% and 83% of subjects treated with RAYALDEE vs. 3% and 7% of subjects treated with placebo (P<0.001) in the two studies, respectively. Average steady-state 25-hydroxyvitamin D levels were 50 and 56 ng/mL for subjects receiving 30 mcg daily, and 69 and 67 ng/mL for subjects receiving 60 mcg daily, in the first and second studies, respectively. Figure 1. Mean (±SE) Percent Change from Baseline in Plasma Intact PTH in the Per Protocol Populations (Pooled Data from Two Phase 3 Studies) The Per Protocol (PP) population consisted of all subjects with at least 2 intact PTH values in the calculated baseline and efficacy assessment period (EAP) values and who did not have a major protocol deviation during the treatment period of the study. The PP population comprised 83% of randomized subjects. Figure 1"],"pharmacodynamics":["12.2 Pharmacodynamics In repeat-dose clinical studies with RAYALDEE, increased levels of serum total 25-hydroxyvitamin D were associated with corresponding increases in serum total 1,25‑dihydroxyvitamin D concentrations and reductions in circulating plasma intact PTH observed within the first two weeks of RAYALDEE treatment [ see Clinical Studies ( 14 ) ]."],"pharmacokinetics":["12.3 Pharmacokinetics Absorption Exposure to calcifediol increased proportionally over the dose range of 30 to 90 mcg following repeated daily administration of RAYALDEE at bedtime to subjects with secondary hyperparathyroidism, chronic kidney disease and vitamin D insufficiency. Steady-state levels of serum total 25-hydroxyvitamin D were reached after approximately 3 months [ see Clinical Studies ( 14 ) ]. Effect of Food Food effect studies with a supratherapeutic dose of RAYALDEE at 450 mcg or 900 mcg in healthy subjects resulted in an approximately 5-fold increase in maximum serum calcifediol concentration ( C max ) and a 3.5-fold increase in AUC 0-t when administered with a high fat, high calorie meal compared to fasting. Distribution Calcifediol is extensively bound to plasma proteins (>98%). The mean apparent volume of distribution is 8.8 L in healthy subjects following a single oral dose of RAYALDEE, and 30.1 L in subjects with stage 3 or 4 chronic kidney disease following repeated dosing. Elimination The mean elimination half-life of calcifediol is approximately 11 days in healthy individuals following a single dose of RAYALDEE, and approximately 25 days in patients with stage 3 or stage 4 chronic kidney disease following repeated once daily dosing. Metabolism Production of calcitriol from calcifediol is catalyzed by the 1-alpha-hydroxylase enzyme, CYP27B1, located in the kidney and other tissues. CYP24A1, located in all vitamin D-responsive tissues, catabolizes both calcifediol and calcitriol to inactive metabolites. Excretion Excretion of calcifediol occurs primarily through the biliary fecal route. Specific Populations Age, gender and race had no meaningful impact on steady-state concentrations of calcifediol following RAYALDEE administration. Patients with Renal Impairment There was no meaningful difference in calcifediol steady-state concentrations following repeated RAYALDEE administration in patients with stage 3 or stage 4 chronic kidney disease. Patients with Hepatic Impairment The pharmacokinetics of calcifediol have not been investigated in patients with hepatic impairment."],"adverse_reactions":["6 ADVERSE REACTIONS The following important adverse reactions are discussed in greater detail in other sections of the label: • Hypercalcemia [ see Warnings and Precautions ( 5.1 ) ] • Adynamic Bone Disease [ see Warnings and Precautions ( 5.3 ) ] The most common adverse reactions (≥3% and more frequent than placebo) were anemia, nasopharyngitis, increased blood creatinine, dyspnea, cough, congestive heart failure and constipation. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact OPKO Pharmaceuticals, LLC at 1-844-729-2539 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trial Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed cannot be directly compared to rates in other trials and may not reflect the rates observed in clinical practice. The data in Table 1 are derived from two pivotal studies described below [ see Clinical Studies ( 14 ) ]. These data reflect exposure of 285 subjects to RAYALDEE 30 or 60 mcg daily for up to 6 months (mean 24 weeks, range 1 to 31 weeks). The mean age of the study population was 66 years old (range 25-85 years). Half of the subjects were male, 65% were White, and 32% were African-American or Black. At baseline, subjects had secondary hyperparathyroidism, stage 3 (52%) or 4 (48%) chronic kidney disease without macroalbuminuria and serum total 25-hydroxyvitamin D levels less than 30 ng/mL. The most common causes of chronic kidney disease were diabetes and hypertension and the mean estimated GFR at baseline was 31 mL/min/1.73m 2 . At baseline, mean plasma intact PTH was 148 pg/mL, mean serum calcium was 9.2 mg/dL, mean serum phosphorus was 3.7 mg/dL and mean serum 25-hydroxyvitamin D was 20 ng/mL. Table 1 shows common adverse reactions associated with the use of RAYALDEE in the pooled placebo-controlled trials. These adverse reactions were not present at baseline, occurred more commonly on RAYALDEE than on placebo, and occurred in at least 1.4% of patients treated with RAYALDEE. Table 1. Common Adverse Reactions in Placebo-controlled Trials Reported in ≥1.4% of RAYALDEE-Treated Subjects Adverse Reaction Placebo N=144 RAYALDEE N=285 % % Anemia 3.5 4.9 Nasopharyngitis 2.8 4.9 Blood creatinine increased 1.4 4.9 Dyspnea 2.8 4.2 Cough 2.1 3.5 Cardiac failure congestive 0.7 3.5 Constipation 2.8 3.2 Bronchitis 0.7 2.8 Hyperkalemia 0.7 2.5 Osteoarthritis 0.7 2.1 Hyperuricemia 0.7 1.8 Contusion 0.0 1.8 Pneumonia 0.7 1.4 Chronic obstructive pulmonary disease 0.0 1.4 Increase in Serum Calcium Patients randomized to RAYALDEE experienced a greater mean (SE) increase in serum calcium (P<0.001) than patients randomized to placebo [i.e., 0.2 (0.02) mg/dL on RAYALDEE versus 0.1 (0.03) mg/dL on placebo from baseline to trial end]. Six subjects (2%) in the RAYALDEE treatment group and no subjects (0%) in the placebo group required dose reductions for protocol-defined hypercalcemia (two consecutive serum calcium values greater than 10.3 mg/dL). A total of 4.2% of RAYALDEE treated subjects and 2.1% of placebo treated subjects experienced at least one elevation in serum calcium above the upper limit of normal (10.5 mg/dL). Increase in Serum Phosphorus Patients randomized to RAYALDEE experienced a greater mean (SE) increase in serum phosphorus than patients randomized to placebo [i.e., 0.2 (0.03) mg/dL on RAYALDEE versus 0.1 (0.04) mg/dL on placebo from baseline to trial end]. One subject (0.4%) in the RAYALDEE treatment group met protocol-defined hyperphosphatemia (two consecutive serum phosphorus values greater than 5.5 mg/dL deemed to be study drug related) compared to no subjects in the placebo group. A total of 45% of RAYALDEE treated subjects and 44% of placebo treated subjects experienced at least one elevation in serum phosphorus above the upper limit of normal (4.5 mg/dL)."],"contraindications":["4 CONTRAINDICATIONS None. None ( 4 )"],"drug_interactions":["7 DRUG INTERACTIONS • Co-administration of cytochrome P450 inhibitors, such as ketoconazole, may alter serum levels of calcifediol. ( 7.1 ) • Co-administration of thiazides may cause hypercalcemia. ( 7.2 ) • Cholestyramine may impair the absorption of calcifediol. ( 7.3 ) • The half-life of calcifediol is reduced by drugs stimulating microsomal hydroxylation, such as phenobarbital or other anticonvulsants. ( 7.4 ) 7.1 CYP3A Inhibitors Cytochrome P450 inhibitors, such as ketoconazole, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole, may inhibit enzymes involved in vitamin D metabolism (CYP24A1 and CYP27B1), and may alter serum levels of calcifediol. Dose adjustment of RAYALDEE may be required, and serum 25-hydroxyvitamin D, intact PTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor. 7.2 Thiazides Thiazides are known to induce hypercalcemia by reducing excretion of calcium in the urine. Concomitant administration of thiazides with RAYALDEE may cause hypercalcemia. Patients may require more frequent serum calcium monitoring in this setting [ see Warnings and Precautions ( 5.1 ) ]. 7.3 Cholestyramine Cholestyramine has been reported to reduce intestinal absorption of fat-soluble vitamins and may impair the absorption of calcifediol, the active ingredient in RAYALDEE. Dose adjustment of RAYALDEE may be required, and serum total 25-hydroxyvitamin D, intact PTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with cholestyramine. 7.4 Other Agents Phenobarbital or other anticonvulsants or other compounds that stimulate microsomal hydroxylation reduce the half-life of calcifediol, the active ingredient in RAYALDEE. Dose adjustment of RAYALDEE may be required, and serum total 25-hydroxyvitamin D, intact PTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with phenobarbital or other anticonvulsants."],"mechanism_of_action":["12.1 Mechanism of Action Calcifediol (25-hydroxyvitamin D 3 ) is a prohormone of the active form of vitamin D 3 , calcitriol (1,25‑dihydroxyvitamin D 3 ). Calcifediol is converted to calcitriol by cytochrome P450 27B1 (CYP27B1), also called 1-alpha hydroxylase, primarily in the kidney. Calcitriol binds to the vitamin D receptor in target tissues and activates vitamin D responsive pathways that result in increased intestinal absorption of calcium and phosphorus and reduced parathyroid hormone synthesis."],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Calcifediol (25-hydroxyvitamin D 3 ) is a prohormone of the active form of vitamin D 3 , calcitriol (1,25‑dihydroxyvitamin D 3 ). Calcifediol is converted to calcitriol by cytochrome P450 27B1 (CYP27B1), also called 1-alpha hydroxylase, primarily in the kidney. Calcitriol binds to the vitamin D receptor in target tissues and activates vitamin D responsive pathways that result in increased intestinal absorption of calcium and phosphorus and reduced parathyroid hormone synthesis. 12.2 Pharmacodynamics In repeat-dose clinical studies with RAYALDEE, increased levels of serum total 25-hydroxyvitamin D were associated with corresponding increases in serum total 1,25‑dihydroxyvitamin D concentrations and reductions in circulating plasma intact PTH observed within the first two weeks of RAYALDEE treatment [ see Clinical Studies ( 14 ) ]. 12.3 Pharmacokinetics Absorption Exposure to calcifediol increased proportionally over the dose range of 30 to 90 mcg following repeated daily administration of RAYALDEE at bedtime to subjects with secondary hyperparathyroidism, chronic kidney disease and vitamin D insufficiency. Steady-state levels of serum total 25-hydroxyvitamin D were reached after approximately 3 months [ see Clinical Studies ( 14 ) ]. Effect of Food Food effect studies with a supratherapeutic dose of RAYALDEE at 450 mcg or 900 mcg in healthy subjects resulted in an approximately 5-fold increase in maximum serum calcifediol concentration ( C max ) and a 3.5-fold increase in AUC 0-t when administered with a high fat, high calorie meal compared to fasting. Distribution Calcifediol is extensively bound to plasma proteins (>98%). The mean apparent volume of distribution is 8.8 L in healthy subjects following a single oral dose of RAYALDEE, and 30.1 L in subjects with stage 3 or 4 chronic kidney disease following repeated dosing. Elimination The mean elimination half-life of calcifediol is approximately 11 days in healthy individuals following a single dose of RAYALDEE, and approximately 25 days in patients with stage 3 or stage 4 chronic kidney disease following repeated once daily dosing. Metabolism Production of calcitriol from calcifediol is catalyzed by the 1-alpha-hydroxylase enzyme, CYP27B1, located in the kidney and other tissues. CYP24A1, located in all vitamin D-responsive tissues, catabolizes both calcifediol and calcitriol to inactive metabolites. Excretion Excretion of calcifediol occurs primarily through the biliary fecal route. Specific Populations Age, gender and race had no meaningful impact on steady-state concentrations of calcifediol following RAYALDEE administration. Patients with Renal Impairment There was no meaningful difference in calcifediol steady-state concentrations following repeated RAYALDEE administration in patients with stage 3 or stage 4 chronic kidney disease. Patients with Hepatic Impairment The pharmacokinetics of calcifediol have not been investigated in patients with hepatic impairment."],"indications_and_usage":["1 INDICATIONS AND USAGE RAYALDEE is a vitamin D 3 analog indicated for the treatment of secondary hyperparathyroidism in adult patients with stage 3 or 4 chronic kidney disease and serum total 25-hydroxyvitamin D levels less than 30 ng/mL. Limitations of Use RAYALDEE is not indicated for the treatment of secondary hyperparathyroidism in patients with stage 5 chronic kidney disease or in patients with end-stage renal disease on dialysis. RAYALDEE is a vitamin D 3 analog indicated for the treatment of secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease and serum total 25-hydroxyvitamin D levels less than 30 ng/mL. ( 1 ) Limitations of Use: RAYALDEE is not indicated in patients with stage 5 chronic kidney disease or end-stage renal disease on dialysis. ( 1 )"],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS • Hypercalcemia: Excessive administration of vitamin D compounds, including RAYALDEE, can cause hypercalcemia and hypercalciuria. Severe hypercalcemia due to substantial overdosage of vitamin D and its metabolites may require emergency attention. Patients should be informed about the symptoms of elevated calcium. ( 5.1 ) • Digitalis toxicity: Potentiated by hypercalcemia of any cause. Monitor serum calcium and signs and symptoms of digitalis toxicity more frequently when initiating or adjusting the dose of RAYALDEE. ( 5.2 ) • Adynamic Bone Disease: Monitor for abnormally low levels of intact PTH levels when using RAYALDEE, and adjust dose if needed. ( 2.2 , 5.3 ) 5.1 Hypercalcemia Hypercalcemia may occur during RAYALDEE treatment [ see Adverse Reactions ( 6.1 ) ]. Acute hypercalcemia may increase the risk of cardiac arrhythmias and seizures and may potentiate the effect of digitalis on the heart [ see Warnings and Precautions ( 5.2 ) ]. Chronic hypercalcemia can lead to generalized vascular calcification and other soft-tissue calcification. Severe hypercalcemia may require emergency attention. Hypercalcemia may be exacerbated by concomitant administration of high doses of calcium containing preparations, thiazide diuretics, or other vitamin D compounds. In addition, high intake of calcium and phosphate concomitantly with vitamin D compounds may lead to hypercalciuria and hyperphosphatemia. In these circumstances, frequent serum calcium monitoring and RAYALDEE dose adjustments may be required. Patients with a history of hypercalcemia prior to initiating therapy with RAYALDEE should be monitored more frequently for possible hypercalcemia during therapy. Patients should be informed about the symptoms of elevated serum calcium, which include feeling tired, difficulty thinking clearly, loss of appetite, nausea, vomiting, constipation, increased thirst, increased urination, and weight loss. 5.2 Digitalis Toxicity Hypercalcemia of any cause, including RAYALDEE [ see Warnings and Precautions ( 5.1 ) ], increases the risk of digitalis toxicity. In patients using RAYALDEE concomitantly with digitalis compounds, monitor both serum calcium and patients for signs and symptoms of digitalis toxicity and increase the frequency of monitoring when initiating or adjusting the dose of RAYALDEE [ see Dosage and Administration ( 2 ) ]. 5.3 Adynamic Bone Disease Adynamic bone disease with subsequent increased risk of fractures may develop if intact PTH levels are suppressed by RAYALDEE to abnormally low levels. Monitor intact PTH levels and adjust RAYALDEE dose, if needed [ see Dosage and Administration ( 2.2 ) ]."],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility No neoplastic changes attributable to calcifediol were observed at subcutaneous doses of 3, 10 and 33 mcg/kg/day in a 26-week rasH2 transgenic mouse study. In vitro or in vivo mutagenicity studies have not been performed with RAYALDEE. Calcifediol has not been shown to have significant effects on fertility in rats."],"adverse_reactions_table":["
Table 1. Common Adverse Reactions in Placebo-controlled Trials Reported in ≥1.4% of RAYALDEE-Treated Subjects
Adverse ReactionPlacebo N=144RAYALDEE N=285
%%
Anemia3.54.9
Nasopharyngitis2.84.9
Blood creatinine increased1.44.9
Dyspnea2.84.2
Cough2.13.5
Cardiac failure congestive0.73.5
Constipation2.83.2
Bronchitis0.72.8
Hyperkalemia0.72.5
Osteoarthritis0.72.1
Hyperuricemia0.71.8
Contusion0.01.8
Pneumonia0.71.4
Chronic obstructive pulmonary disease 0.01.4
"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION • Inform patients to take RAYALDEE at bedtime and to swallow the capsules whole. • Inform patients if they miss a dose, to take RAYALDEE at the next scheduled time. Do not take an extra dose to make up for the missed dose. • Inform patients that they will need routine monitoring of laboratory parameters such as calcium, iPTH and total 25-hydroxyvitamin D while taking RAYALDEE. • Advise patients to contact a health care provider if they develop symptoms of elevated calcium (e.g., feeling tired, having difficulty thinking clearly, loss of appetite, nausea, vomiting, constipation, increased thirst, increased urination or weight loss). • Advise patients to inform their physician of all use of medications, including prescription and nonprescription drugs, supplements and herbal preparations, and of any changes in medical condition. Patients should also be advised to inform their physicians, when receiving a newly prescribed medication, that they are taking RAYALDEE. • Inform lactating women about the need to monitor infants exposed to RAYALDEE through breast milk for signs of hypercalcemia to include seizures, vomiting, constipation and weight loss [ see Use in Specific Populations ( 8.2 ) ] . RAYALDEE ® is a registered trademark of Eirgen Pharma Ltd. Patent: https://www.opko.com/what-we-do/our-research/patents Manufactured for: OPKO Pharmaceuticals, LLC 4400 Biscayne Blvd. Miami FL 33137 USA © 2024 OPKO Pharmaceuticals, LLC. All rights reserved."],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION • The initial dose of RAYALDEE is 30 mcg administered orally once daily at bedtime. Serum calcium should be below 9.8 mg/dL before initiating treatment. ( 2 ) • Monitor serum calcium, phosphorus, 25-hydroxyvitamin D and intact parathyroid hormone (PTH) 3 months after starting therapy or changing dose. ( 2.2 , 5.3 ) • Increase the dose to 60 mcg once daily after 3 months if intact PTH is above the treatment goal. Ensure serum calcium is below 9.8 mg/dL, phosphorus is below 5.5 mg/dL and 25-hydroxyvitamin D is below 100 ng/mL before increasing the dose. ( 2.2 ) • Suspend dosing if intact PTH is persistently abnormally low, serum calcium is consistently above the normal range or serum 25-hydroxyvitamin D is consistently above 100 ng/mL. ( 2.2 ) 2.1 Important Dosage and Administration Information • Ensure serum calcium is below 9.8 mg/dL before initiating treatment [ see Warnings and Precautions ( 5.1 ) ]. • Instruct patients to swallow RAYALDEE capsules whole. • Instruct patients to skip a missed dose and to resume taking the medicine at the next regularly scheduled time. Do not administer an extra dose. 2.2 Starting Dose and Dose Titration • The initial dose of RAYALDEE is 30 mcg administered orally once daily at bedtime. • The maintenance dose of RAYALDEE should target serum total 25-hydroxyvitamin D levels between 30 and 100 ng/mL, intact parathyroid hormone (PTH) levels within the desired therapeutic range, serum calcium (corrected for low albumin) within the normal range and serum phosphorus below 5.5 mg/dL. • Monitor serum calcium, serum phosphorus, serum total 25-hydroxyvitamin D and intact PTH levels at a minimum of 3 months after initiation of therapy or dose adjustment, and subsequently at least every 6 to 12 months. • Increase the dose to 60 mcg orally once daily at bedtime after approximately 3 months, if intact PTH remains above the desired therapeutic range. Prior to raising the dose, ensure serum calcium is below 9.8 mg/dL, serum phosphorus is below 5.5 mg/dL and serum total 25-hydroxyvitamin D is below 100 ng/mL. • Suspend dosing if intact PTH is persistently and abnormally low to reduce the risk of adynamic bone disease [ see Warnings and Precautions ( 5.3 ) ], if serum calcium is consistently above the normal range to reduce the risk of hypercalcemia [ see Warnings and Precautions ( 5.1 ) ], or if serum total 25-hydroxyvitamin D is consistently above 100 ng/mL. Restart at a reduced dose after these laboratory values have normalized."],"spl_product_data_elements":["Rayaldee calcifediol CALCIFEDIOL CALCIFEDIOL ANHYDROUS PARAFFIN MINERAL OIL HYPROMELLOSE, UNSPECIFIED GLYCERYL MONO- AND DIPALMITOSTEARATE LAUROYL PEG-32 GLYCERIDES ALCOHOL BUTYLATED HYDROXYTOLUENE MEDIUM-CHAIN TRIGLYCERIDES HYDROXYPROPYL CORN STARCH (5% SUBSTITUTION BY WEIGHT) CARRAGEENAN SODIUM PHOSPHATE, DIBASIC, UNSPECIFIED FORM SORBITOL SORBITAN FD&C BLUE NO. 1 TITANIUM DIOXIDE WATER O Rayaldee calcifediol CALCIFEDIOL CALCIFEDIOL ANHYDROUS PARAFFIN MINERAL OIL HYPROMELLOSE, UNSPECIFIED GLYCERYL MONO- AND DIPALMITOSTEARATE LAUROYL PEG-32 GLYCERIDES ALCOHOL BUTYLATED HYDROXYTOLUENE TITANIUM DIOXIDE GELLAN GUM (LOW ACYL) O;30"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Extended-release capsules, 30 mcg available as: • blue oval soft capsules imprinted with “O” in white ink • White two-piece banded hard capsules imprinted with ”O” and “30” in blue ink Extended-release capsules: 30 mcg ( 3 )"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS • Lactation: Monitor infants exposed to RAYALDEE through breast milk for seizures, vomiting, constipation and weight loss. ( 8.2 ) 8.1 Pregnancy Risk Summary There are no human data with calcifediol use in pregnant women to identify a drug-associated risk for major birth defects, miscarriage or adverse maternal or fetal outcomes. There are risks to the mother and fetus associated with chronic kidney disease in pregnancy (see Clinical Considerations ) . In animal reproduction studies, calcifediol increased skeletal and soft tissue malformation when rabbits were given once daily oral doses representing ≥8 times the human dose of 60 mcg/day, based on body surface area (mg/m 2 ), during the period of organogenesis. No adverse developmental effects were observed in rats given up to 10 times the human dose, based on body surface area (mg/m 2 ), during organogenesis. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. Clinical Considerations Disease-associated maternal and/or embryo/fetal risk Chronic kidney disease in pregnancy increases the maternal risk for hypertension, miscarriage, preterm labor, and preeclampsia. Chronic kidney disease increases the fetal risk for intrauterine growth restriction (IUGR), prematurity, polyhydramnios, still birth, and low birth weight. Data Animal Data Calcifediol was given orally to pregnant rats and rabbits during the period of organogenesis (in rats, from gestation day [GD] 6 to 15; in rabbits, from GD 6 to 18). Rats were given 0, 12, 40, 60 mcg/kg/day; and rabbits were given 0, 5, 25, 50 mcg/kg/day, representing up to 10 and 16 times, respectively, a human dose of 60 mcg/day, based on body surface area (mg/m 2 ). In rats, no adverse developmental effects were observed at calcifediol doses up to 60 mcg/kg/day. In rabbits, increased incidences of domed skull, enlarged atrium of the heart, and dilatation of pulmonary artery, were observed at doses of 25 and 50 mcg/kg/day (representing 8 and 16 times the human dose of 60 mcg/day, respectively, based on body surface area (mg/m 2 ). Rats were given calcifediol during the pre/postnatal period (GD 15 to weaning). No adverse effects on gestation, parturition, lactation or survival of offspring were observed at calcifediol doses up to 60 mcg/kg/day. 8.2 Lactation Risk Summary There is no information available on the presence of calcifediol in human milk, the effects of the drug on the breastfed infant, or the effects of the drug on milk production. Infants potentially exposed to calcifediol through breast milk should be monitored for signs and symptoms of hypercalcemia (see Clinical Considerations ) . The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for RAYALDEE and any potential adverse effects on the breastfed child from RAYALDEE or from the underlying maternal condition. Clinical Considerations Monitor infants exposed to calcifediol through breast milk for signs and symptoms of hypercalcemia, including seizures, vomiting, constipation and weight loss. Consider monitoring of serum calcium in the infant. 8.4 Pediatric Use The safety and efficacy of RAYALDEE have not been established in pediatric patients. 8.5 Geriatric Use Of the total number of subjects in phase 3 placebo-controlled clinical studies of RAYALDEE, 63% were ≥65 years of age and 22% were ≥75 years of age. No overall differences in the safety or efficacy of RAYALDEE were observed between subjects older than 65 years and younger subjects. 8.6 Renal Impairment No difference in efficacy was observed between patients with stage 3 chronic kidney disease or those with stage 4 disease in subgroup analysis. Safety outcomes were similar in these subgroups. The safety and efficacy of RAYALDEE in the treatment of secondary hyperparathyroidism in patients with stage 2 or stage 5 chronic kidney disease and patients with end-stage renal disease on dialysis have not been established [ see Indications and Usage ( 1 ) ]."],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL NDC: 70301-1001-1 - 30-count Bottle Label 30-count Soft Capsule Bottle Label NDC 70301-1001-1 OPKO Rayaldee ® (calcifediol) Extended-Release Capsules 30 mcg Rx only Each capsule contains: 30 mcg calcifediol See package insert for full prescribing information 30 Capsules Manufactured for: OPKO Pharmaceuticals, LLC 4400 Biscayne Blvd Miami FL 33137 Rev. 03/21 PC2192 Store between 20 - 25°C (68-77°F) excursions permitted to 15 - 30°C (59 - 86°F) see [USP controlled room temperature] Principal Display Panel NDC: 70301-1001-1: 30-count Soft Capsule Bottle Label","PRINCIPAL DISPLAY PANEL NDC: 70301-1002-1 - 30-count Bottle Label 30-count Hard Capsule Bottle Label NDC 70301-1002-1 OPKO Rx only Rayaldee ® calcifediol ER capsules 30 mcg Each capsule contains: 30 mcg calcifediol See package insert for full prescribing information 30 Capsules Manufactured for: OPKO Pharmaceuticals, LLC 4400 Biscayne Blvd Miami FL 33137 Rev. 06/24 PC2569 Store between 20 - 25°C (68-77°F) excursions permitted to 15 - 30°C (59 - 86°F) see [USP controlled room temperature] Principal Display Panel NDC: 70301-1002-1: 30-count Hard Capsule Bottle Label"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility No neoplastic changes attributable to calcifediol were observed at subcutaneous doses of 3, 10 and 33 mcg/kg/day in a 26-week rasH2 transgenic mouse study. In vitro or in vivo mutagenicity studies have not been performed with RAYALDEE. Calcifediol has not been shown to have significant effects on fertility in rats."]},"tags":[{"label":"calcifediol","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Sterol regulatory element-binding protein 1","category":"target"},{"label":"SREBF1","category":"gene"},{"label":"VDR","category":"gene"},{"label":"A11CC06","category":"atc"},{"label":"Oral","category":"route"},{"label":"Capsule","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Active","category":"status"},{"label":"Hypocalcemia","category":"indication"},{"label":"Hypophosphatemia","category":"indication"},{"label":"Renal osteodystrophy","category":"indication"},{"label":"Rickets","category":"indication"},{"label":"Approved 1980s","category":"decade"},{"label":"Bone Density Conservation Agents","category":"pharmacology"},{"label":"Micronutrients","category":"pharmacology"},{"label":"Vitamins","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"DEATH","source":"FDA FAERS","actionTaken":"180 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"112 reports"},{"date":"","signal":"ACUTE KIDNEY INJURY","source":"FDA FAERS","actionTaken":"99 reports"},{"date":"","signal":"DRUG INTERACTION","source":"FDA FAERS","actionTaken":"98 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"66 reports"},{"date":"","signal":"COVID-19","source":"FDA FAERS","actionTaken":"63 reports"},{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"63 reports"},{"date":"","signal":"HYPOTENSION","source":"FDA FAERS","actionTaken":"61 reports"},{"date":"","signal":"ANAEMIA","source":"FDA FAERS","actionTaken":"60 reports"},{"date":"","signal":"PNEUMONIA","source":"FDA FAERS","actionTaken":"60 reports"}],"commonSideEffects":[{"effect":"Anemia","drugRate":"4.9%","severity":"common","_validated":true},{"effect":"Nasopharyngitis","drugRate":"4.9%","severity":"common","_validated":true},{"effect":"Increased blood creatinine","drugRate":"4.9%","severity":"common","_validated":true},{"effect":"Dyspnea","drugRate":"4.2%","severity":"common","_validated":true},{"effect":"Cough","drugRate":"3.5%","severity":"common","_validated":true},{"effect":"Cardiac failure congestive","drugRate":"3.5%","severity":"common","_validated":true},{"effect":"Constipation","drugRate":"3.2%","severity":"common","_validated":true},{"effect":"Bronchitis","drugRate":"2.8%","severity":"mild","_validated":true},{"effect":"Hyperkalemia","drugRate":"2.5%","severity":"mild","_validated":true},{"effect":"Osteoarthritis","drugRate":"2.1%","severity":"mild","_validated":true},{"effect":"Hyperuricemia","drugRate":"1.8%","severity":"mild","_validated":true},{"effect":"Contusion","drugRate":"1.8%","severity":"mild","_validated":true},{"effect":"Pneumonia","drugRate":"1.4%","severity":"mild","_validated":true},{"effect":"Chronic obstructive pulmonary disease","drugRate":"1.4%","severity":"mild","_validated":true},{"effect":"Increase in Serum Calcium","drugRate":"4.2%","severity":"common","_validated":true},{"effect":"Increase in Serum Phosphorus","drugRate":"45%","severity":"serious","_validated":true}],"contraindications":["Arteriosclerosis obliterans","Hypercalcemia","Hyperphosphatemia","Hypervitaminosis D","Kidney disease","Kidney stone","Sarcoidosis"],"specialPopulations":{"Lactation":"There is no information available on the presence of calcifediol in human milk, the effects of the drug on the breastfed infant, or the effects of the drug on milk production. Infants potentially exposed to calcifediol through breast milk should be monitored for signs and symptoms of hypercalcemia (see Clinical Considerations). The developmental and health benefits of breastfeeding should be considered along with the mothers clinical need for RAYALDEE and any potential risks to the infant.","Pregnancy":"There are no human data with calcifediol use in pregnant women to identify drug-associated risk for major birth defects, miscarriage or adverse maternal or fetal outcomes. There are risks to the mother and fetus associated with chronic kidney disease in pregnancy (see Clinical Considerations). In animal reproduction studies, calcifediol increased skeletal and soft tissue malformation when rabbits were given once daily oral doses representing >=6 times the human dose of 60 mcg/day, based on body surface area (mg/m2), during the period of organogenesis. No adverse developmental effects were observed in rats given up to 15 times the human dose, based on body surface area (mg/m2), during organogenesis.The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.. Clinical Considerations. Disease-associated maternal and/or embryo/fetal risk Chronic kidney disease in pregnancy increases the maternal risk for hypertension, miscarriage, preterm labor, and p","Geriatric use":"Of the total number of subjects in phase placebo-controlled clinical studies of RAYALDEE, 63% were >=65 years of age and 22% were >=75 years of age. No overall differences in the safety or efficacy of RAYALDEE were observed between subjects older than 65 years and younger subjects.","Paediatric use":"The safety and efficacy of RAYALDEE have not been established in pediatric patients."}},"trials":[],"aliases":[],"patents":[{"type":"Method of Use","number":"8778373","applicant":"EIRGEN PHARMA LTD","territory":"US","tradeName":"RAYALDEE","expiryDate":"2028-04-25"},{"type":"Method of Use","number":"9408858","applicant":"EIRGEN PHARMA LTD","territory":"US","tradeName":"RAYALDEE","expiryDate":"2028-04-25"},{"type":"Method of Use","number":"9943530","applicant":"EIRGEN PHARMA LTD","territory":"US","tradeName":"RAYALDEE","expiryDate":"2027-02-02"},{"type":"Formulation","number":"9925147","applicant":"EIRGEN PHARMA LTD","territory":"US","tradeName":"RAYALDEE","expiryDate":"2028-04-25"},{"type":"Method of Use","number":"8207149","applicant":"EIRGEN PHARMA LTD","territory":"US","tradeName":"RAYALDEE","expiryDate":"2028-04-25"},{"type":"Method of Use","number":"8426391","applicant":"EIRGEN PHARMA LTD","territory":"US","tradeName":"RAYALDEE","expiryDate":"2028-08-27"},{"type":"Formulation","number":"11801253","applicant":"EIRGEN PHARMA LTD","territory":"US","tradeName":"RAYALDEE","expiryDate":"2030-09-07"},{"type":"Method of Use","number":"9498486","applicant":"EIRGEN PHARMA LTD","territory":"US","tradeName":"RAYALDEE","expiryDate":"2028-04-25"},{"type":"Method of Use","number":"11154509","applicant":"EIRGEN PHARMA LTD","territory":"US","tradeName":"RAYALDEE","expiryDate":"2028-04-25"},{"type":"Formulation","number":"9861644","applicant":"EIRGEN PHARMA LTD","territory":"US","tradeName":"RAYALDEE","expiryDate":"2034-03-14"},{"type":"Formulation","number":"8361488","applicant":"EIRGEN PHARMA LTD","territory":"US","tradeName":"RAYALDEE","expiryDate":"2028-07-19"},{"type":"Formulation","number":"10300078","applicant":"EIRGEN PHARMA LTD","territory":"US","tradeName":"RAYALDEE","expiryDate":"2034-03-14"},{"type":"Formulation","number":"10357502","applicant":"EIRGEN PHARMA LTD","territory":"US","tradeName":"RAYALDEE","expiryDate":"2034-03-14"},{"type":"Formulation","number":"10213442","applicant":"EIRGEN PHARMA LTD","territory":"US","tradeName":"RAYALDEE","expiryDate":"2027-02-02"},{"type":"Formulation","number":"11253528","applicant":"EIRGEN PHARMA LTD","territory":"US","tradeName":"RAYALDEE","expiryDate":"2034-03-14"},{"type":"Formulation","number":"8906410","applicant":"EIRGEN PHARMA LTD","territory":"US","tradeName":"RAYALDEE","expiryDate":"2027-02-02"}],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=CALCIFEDIOL","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:00:53.923145+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T00:00:53.923075+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Calcifediol","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T00:01:02.139400+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:01:00.096788+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T00:00:52.766564+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CALCIFEDIOL","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:01:00.996405+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:00:51.653783+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:00:51.653811+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T00:01:03.299848+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Vitamin D receptor agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:01:02.139334+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3544909/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:01:01.790086+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"NDA208010","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:00:51.653815+00:00"}},"allNames":"rayaldee","offLabel":[],"synonyms":["calcifediol","calcidiol","calderol"],"timeline":[{"date":"1980-08-05","type":"positive","source":"DrugCentral","milestone":"FDA approval"},{"date":"2016-06-17","type":"positive","source":"FDA Orange Book","milestone":"Rayaldee approved — 0.03MG"}],"aiSummary":"Rayaldee (calcifediol) is a small molecule modality that targets sterol regulatory element-binding protein 1. Originally developed, it is now owned by Eirgen and was FDA approved in 1980 for the treatment of hypocalcemia, hypophosphatemia, renal osteodystrophy, and rickets. As an off-patent calcifediol, it is not commercially available as a generic. Key safety considerations include its long half-life of 11 days. Rayaldee is used to treat conditions related to low calcium levels in the blood.","brandName":"Rayaldee","ecosystem":[{"indication":"Hypocalcemia","otherDrugs":[{"name":"calcitriol","slug":"calcitriol","company":"Validus Pharms"},{"name":"calcium acetate","slug":"calcium-acetate","company":"B Braun"},{"name":"calcium carbonate","slug":"calcium-carbonate","company":"Mcneil Cons"},{"name":"calcium chloride","slug":"calcium-chloride","company":"Baxter Hlthcare"}],"globalPrevalence":null},{"indication":"Hypophosphatemia","otherDrugs":[{"name":"calcitriol","slug":"calcitriol","company":"Validus Pharms"},{"name":"sodium glycerophosphate","slug":"sodium-glycerophosphate","company":"Fresenius Kabi Usa"},{"name":"sodium phosphate, monobasic","slug":"sodium-phosphate,-monobasic","company":""},{"name":"sodium phosphate, monobasic, monohydrate","slug":"sodium-phosphate,-monobasic,-monohydrate","company":"Salix Pharms"}],"globalPrevalence":null},{"indication":"Renal osteodystrophy","otherDrugs":[{"name":"calcitriol","slug":"calcitriol","company":"Validus Pharms"}],"globalPrevalence":null},{"indication":"Rickets","otherDrugs":[{"name":"colecalciferol","slug":"colecalciferol","company":"Sandoz"},{"name":"ergocalciferol","slug":"ergocalciferol","company":"Sanofi Aventis Us"}],"globalPrevalence":null}],"mechanism":{"target":"Sterol regulatory element-binding protein 1","novelty":"Follow-on","targets":[{"gene":"SREBF1","source":"DrugCentral","target":"Sterol regulatory element-binding protein 1","protein":"Sterol regulatory element-binding protein 1"},{"gene":"VDR","source":"DrugCentral","target":"Vitamin D3 receptor","protein":"Vitamin D3 receptor"}],"modality":"Small Molecule","drugClass":"calcifediol","explanation":"Calcifediol (25-hydroxyvitamin D3) is prohormone of the active form of vitamin D3, calcitriol (1,25-dihydroxyvitamin D3). Calcifediol is converted to calcitriol by cytochrome P450 27B1 (CYP27B1), also called 1-alpha hydroxylase, primarily in the kidney. Calcitriol binds to the vitamin receptor in target tissues and activates vitamin responsive pathways that result in increased intestinal absorption of calcium and phosphorus and reduced parathyroid hormone synthesis.","oneSentence":"Rayaldee works by increasing the levels of active vitamin D in the body.","technicalDetail":"Rayaldee (calcifediol) acts as a pro-hormone that is converted to its active form, calcitriol, in the liver and kidneys, which then targets the sterol regulatory element-binding protein 1 (SREBP-1) to increase the expression of genes involved in calcium absorption and bone mineralization.","_target_confidence":0.5},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Calcifediol","title":"Calcifediol","extract":"Calcifediol, also known as calcidiol, 25-hydroxycholecalciferol, or 25-hydroxyvitamin D3 (abbreviated 25(OH)D3), is a form of vitamin D produced in the liver by hydroxylation of vitamin D3 (cholecalciferol) by the enzyme vitamin D 25-hydroxylase. Calcifediol can be further hydroxylated by the enzyme 25(OH)D-1α-hydroxylase, primarily in the kidney, to form calcitriol (1,25-(OH)2D3), which is the active hormonal form of vitamin D.","wiki_history":"==History==\nResearch in the laboratory of Hector DeLuca identified 25(OH)D in 1968 and showed that the liver was necessary for its formation. The enzyme responsible for this synthesis, cholecalciferol 25-hydroxylase, was isolated in the same laboratory by Michael F. Holick in 1972."},"commercial":{"launchDate":"1980","_launchSource":"DrugCentral (FDA 1980-08-05, )"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/464","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=CALCIFEDIOL","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CALCIFEDIOL","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Calcifediol","fields":["history","overview"],"source":"Wikipedia"},{"id":5,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T09:07:48.523374","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:01:10.652200+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"ergocalciferol","drugSlug":"ergocalciferol","fdaApproval":"1941-01-11","genericCount":13,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"calcitriol","drugSlug":"calcitriol","fdaApproval":"1978-08-17","genericCount":18,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"colecalciferol","drugSlug":"colecalciferol","fdaApproval":"2000-05-18","relationship":"same-class"}],"genericName":"calcifediol","indications":{"approved":[{"name":"Hypocalcemia","source":"DrugCentral","snomedId":5291005,"regulator":"FDA"},{"name":"Hypophosphatemia","source":"DrugCentral","snomedId":4996001,"regulator":"FDA"},{"name":"Renal osteodystrophy","source":"DrugCentral","snomedId":16726004,"regulator":"FDA"},{"name":"Rickets","source":"DrugCentral","snomedId":41345002,"regulator":"FDA"}],"offLabel":[{"name":"Vitamin D deficiency","source":"DrugCentral","drugName":"CALCIFEDIOL","evidenceCount":1980,"evidenceLevel":"strong"}],"pipeline":[]},"currentOwner":"Eirgen","drugCategory":"active","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"ergocalciferol","brandName":"ergocalciferol","genericName":"ergocalciferol","approvalYear":"1941","relationship":"same-class"},{"drugId":"calcitriol","brandName":"calcitriol","genericName":"calcitriol","approvalYear":"1978","relationship":"same-class"},{"drugId":"colecalciferol","brandName":"colecalciferol","genericName":"colecalciferol","approvalYear":"2000","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07479303","phase":"","title":"Vitamin D Status in Young Medical Residents","status":"COMPLETED","sponsor":"Maimónides Biomedical Research Institute of Córdoba","startDate":"2025-10-29","conditions":["Vitamin D Deficiency"],"enrollment":30,"completionDate":"2025-12-01"},{"nctId":"NCT07438977","phase":"NA","title":"Evaluation of Serum TRACP-5b, BALP, and 25-Hydroxyvitamin D3 Levels in Stage III Periodontitis Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ataturk University","startDate":"2024-12-05","conditions":["Stage III Periodontitis"],"enrollment":16,"completionDate":"2026-03-15"},{"nctId":"NCT01698840","phase":"NA","title":"Effect of Vitamin D in Diets of Preterm Infants","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2013-01","conditions":["Premature Infants"],"enrollment":39,"completionDate":"2016-07-30"},{"nctId":"NCT07057362","phase":"","title":"Effect of Vitamin D Deficiency on the Frequency and Severity of Spinal Anesthesia-Induced Hypotension in Pregnant Women Undergoing Cesarean Section","status":"RECRUITING","sponsor":"Duzce University","startDate":"2025-03-01","conditions":["Spinal Anesthesia-induced Hypotension","Vitamin D Deficiency","Cesarean Section"],"enrollment":140,"completionDate":"2025-12-30"},{"nctId":"NCT07300332","phase":"NA","title":"Exercise Training and Vitamin D Metabolism","status":"RECRUITING","sponsor":"University of Thessaly","startDate":"2025-11-10","conditions":["Obesity & Overweight","Vitamin D"],"enrollment":30,"completionDate":"2026-07-20"},{"nctId":"NCT03348280","phase":"","title":"Vitamin D and Immune Mechanisms of Hypertension in Type 2 Diabetics","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2017-09-01","conditions":["Diabetes Mellitus, Type 2","Hypertension","Vitamin D Deficiency"],"enrollment":40,"completionDate":"2026-12-31"},{"nctId":"NCT07269223","phase":"NA","title":"Oral Vitamin D3 Effect on Inflammatory Biomarkers in Ulcerative Colitis Patients","status":"RECRUITING","sponsor":"University of Veterinary and Animal Sciences, Lahore - Pakistan","startDate":"2025-09-02","conditions":["Ulcerative Colitis (UC)"],"enrollment":60,"completionDate":"2025-12-30"},{"nctId":"NCT06138249","phase":"NA","title":"Cholecalciferol and Calcifediol Are Both Useful to Improve Vitamin D Serum Levels","status":"RECRUITING","sponsor":"Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari","startDate":"2023-07-01","conditions":["Hypovitaminosis D"],"enrollment":90,"completionDate":"2025-12-30"},{"nctId":"NCT05845021","phase":"NA","title":"Surgeon-Initiated Bone Health Referral Pathway in Patients Undergoing Lower Extremity Arthroplasty","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2023-09-27","conditions":["Osteoporosis","Arthroplasty Complications","Fragility Fracture"],"enrollment":2000,"completionDate":"2028-07"},{"nctId":"NCT02962102","phase":"PHASE2","title":"Activated Vitamin D for the Prevention and Treatment of Acute Kidney Injury","status":"COMPLETED","sponsor":"David Leaf","startDate":"2017-04-03","conditions":["Critically Ill","Acute Kidney Injury"],"enrollment":150,"completionDate":"2020-08-06"},{"nctId":"NCT05431920","phase":"NA","title":"Effects of Vitamin D Supplementation in Adolescents With Asthma, Obesity and Vitamin D Deficiency.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hospital Infantil de Mexico Federico Gomez","startDate":"2022-10-01","conditions":["Non-allergic Asthma","Obesity","Vitamin D Deficiency"],"enrollment":264,"completionDate":"2026-12-31"},{"nctId":"NCT06943443","phase":"NA","title":"Effect of Serum Vitamin D on MARPE Treatment Response","status":"ENROLLING_BY_INVITATION","sponsor":"Konya Necmettin Erbakan Üniversitesi","startDate":"2025-02-20","conditions":["Maxillary Transverse Deficiency Class I Malocclusion Vitamin D Deficiency Orthodontic Tooth Movement Adolescent Health"],"enrollment":20,"completionDate":"2025-11-25"},{"nctId":"NCT07123337","phase":"","title":"Serum 25-Hydroxyvitamin D and Neurological Disability in Multiple Sclerosis","status":"COMPLETED","sponsor":"University of Zintan","startDate":"2023-08-01","conditions":["Multiple Sclerosis"],"enrollment":369,"completionDate":"2025-04-08"},{"nctId":"NCT07096336","phase":"NA","title":"Effect of Vitamin D3 on Brain Waves in Male Parkinson's Patients With Low Vitamin D: A qEEG Study","status":"RECRUITING","sponsor":"Bangladesh Medical University","startDate":"2025-07-15","conditions":["PARKINSON DISEASE (Disorder)"],"enrollment":15,"completionDate":"2025-11"},{"nctId":"NCT05543928","phase":"PHASE3","title":"Phase 3 Safety and Efficacy Study of CTAP101 Extended-release Capsules in Children With Secondary Hyperparathyroidism","status":"TERMINATED","sponsor":"OPKO Health, Inc.","startDate":"2023-01-31","conditions":["Chronic Kidney Disease stage3","Chronic Kidney Disease stage4","Vitamin d Deficiency","Secondary Hyperparathyroidism"],"enrollment":2,"completionDate":"2024-06-19"},{"nctId":"NCT05460234","phase":"","title":"RAYALDEE Non Interventional Study (NIS) on Effectiveness in ND-CKD SHPT Patients","status":"COMPLETED","sponsor":"Vifor (International) Inc.","startDate":"2022-10-05","conditions":["Chronic Kidney Disease"],"enrollment":110,"completionDate":"2025-06-30"},{"nctId":"NCT06279910","phase":"","title":"Calcifediol in the Treatment of SARS-CoV-2 Disease (COVID-19).","status":"COMPLETED","sponsor":"Complejo Hospitalario Universitario de Albacete","startDate":"2024-02-21","conditions":["SARS-CoV 2 Pneumonia"],"enrollment":230,"completionDate":"2024-04-25"},{"nctId":"NCT05096195","phase":"PHASE4","title":"PRevEnting FracturEs in REnal Disease - 1","status":"ACTIVE_NOT_RECRUITING","sponsor":"Western University, Canada","startDate":"2022-06-11","conditions":["Kidney Diseases","Dialysis; Complications","Fragility Fracture","Chronic Kidney Disease-Mineral and Bone Disorder"],"enrollment":60,"completionDate":"2025-12"},{"nctId":"NCT06634316","phase":"NA","title":"Sarcopenia in Patients With Heart Failure","status":"ACTIVE_NOT_RECRUITING","sponsor":"Maimónides Biomedical Research Institute of Córdoba","startDate":"2024-11-15","conditions":["Sarcopenia"],"enrollment":60,"completionDate":"2026-12-31"},{"nctId":"NCT03602261","phase":"PHASE2","title":"Safety, Efficacy, PK and PD of CTAP101 (Calcifediol) ER Capsules for SHPT in HD Patients VDI","status":"TERMINATED","sponsor":"OPKO Health, Inc.","startDate":"2018-07-09","conditions":["Secondary Hyperparathyroidism Due to Renal Causes","Chronic Kidney Diseases","Vitamin D Deficiency","Stage 5 Chronic Kidney Disease"],"enrollment":44,"completionDate":"2021-02-24"},{"nctId":"NCT06871631","phase":"","title":"Serum Vitamin D and Gingival Crevicular Fluid Levels of Osteocalcin and N-Terminal Telopeptide","status":"COMPLETED","sponsor":"Ondokuz Mayıs University","startDate":"2018-06-10","conditions":["D Vitamin Deficiency","Osteocalcin","Gingival Crevicular Fluid"],"enrollment":120,"completionDate":"2025-02-15"},{"nctId":"NCT01651000","phase":"PHASE3","title":"Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency","status":"COMPLETED","sponsor":"OPKO IP Holdings II, Inc.","startDate":"2012-09","conditions":["Chronic Kidney Disease","Hyperparathyroidism, Secondary","Vitamin D Deficiency"],"enrollment":213,"completionDate":"2014-07"},{"nctId":"NCT01704079","phase":"PHASE3","title":"Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency","status":"COMPLETED","sponsor":"OPKO IP Holdings II, Inc.","startDate":"2012-11","conditions":["Chronic Kidney Disease","Hyperparathyroidism, Secondary","Vitamin D Deficiency"],"enrollment":216,"completionDate":"2014-09"},{"nctId":"NCT02506439","phase":"NA","title":"Nutritional Requirements for Vitamin D in Pregnant Women","status":"COMPLETED","sponsor":"University College Cork","startDate":"2014-11-01","conditions":["Vitamin D Deficiency"],"enrollment":144,"completionDate":"2017-04-01"},{"nctId":"NCT04780776","phase":"NA","title":"Evaluating the Effect of SOLIUS UV Light Source in Improving Vitamin D Status","status":"COMPLETED","sponsor":"Boston University","startDate":"2022-02-23","conditions":["Vitamin D Deficiency","Vitamin D Insufficiency"],"enrollment":69,"completionDate":"2023-11-02"},{"nctId":"NCT06571344","phase":"","title":"Vitamin D in Dialysis Patients - Diagnostic and Therapeutic Management","status":"RECRUITING","sponsor":"Medical University of Gdansk","startDate":"2022-11-01","conditions":["Vitamin D Deficiency Due to Chronic Kidney Disease"],"enrollment":160,"completionDate":"2026-12-31"},{"nctId":"NCT05937789","phase":"NA","title":"Early Vitamin D3 Supplementation for Critically Ill Patients","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2024-01-22","conditions":["Vitamin D Deficiency","Critical Illness"],"enrollment":240,"completionDate":"2026-12-31"},{"nctId":"NCT06551337","phase":"PHASE4","title":"Vitamin D Replacement in Bronchiectasis","status":"RECRUITING","sponsor":"Queen Mary Hospital, Hong Kong","startDate":"2024-04-17","conditions":["Bronchiectasis"],"enrollment":104,"completionDate":"2027-06-30"},{"nctId":"NCT02333682","phase":"NA","title":"Pharmacokinetics of Calcifediol and Cholecalciferol","status":"COMPLETED","sponsor":"dsm-firmenich Switzerland AG","startDate":"2014-11","conditions":["Osteoporosis"],"enrollment":93,"completionDate":"2015-12"},{"nctId":"NCT01419119","phase":"PHASE4","title":"Vitamin Deficiency in Immigrants, a Treatment Study","status":"COMPLETED","sponsor":"Umeå University","startDate":"2011-09","conditions":["Vitamin D Deficiency"],"enrollment":160,"completionDate":"2012-10"},{"nctId":"NCT04551911","phase":"PHASE2","title":"Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19","status":"COMPLETED","sponsor":"OPKO Health, Inc.","startDate":"2020-11-02","conditions":["COVID-19","Coronavirus","SARS-CoV2 Infection"],"enrollment":171,"completionDate":"2021-10-08"},{"nctId":"NCT06101589","phase":"NA","title":"Effect of Vitamin D Supplementation on Allostatic Load and Chronic Stress Along Line of Control in Azad Jammu Kashmir","status":"NOT_YET_RECRUITING","sponsor":"University of the Punjab","startDate":"2024-05-15","conditions":["Mental Health Issue"],"enrollment":120,"completionDate":"2024-09-15"},{"nctId":"NCT01437111","phase":"PHASE3","title":"Study of MK-217A/Alendronate Sodium 70-mg/Vitamin D3 5600 IU Combination Tablet (MK-0217A-329)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2011-10-26","conditions":["Osteoporosis"],"enrollment":200,"completionDate":"2012-12-05"},{"nctId":"NCT05398939","phase":"","title":"Impact of COVID-19 Vaccination on Serum 25-hydroxyvitamin D Level","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2022-05-25","conditions":["Acne Vulgaris","Vitamin D Deficiency","COVID-19"],"enrollment":20,"completionDate":"2022-11-29"},{"nctId":"NCT06292195","phase":"","title":"Effects of Vitamin D on Health Promotion During Pregnancy and Its Impact on Prematurity-Related Outcome","status":"RECRUITING","sponsor":"University of Évora","startDate":"2023-11-03","conditions":["Vitamin D Deficiency","Pregnancy"],"enrollment":1000,"completionDate":"2025-12-31"},{"nctId":"NCT05264610","phase":"","title":"Retrospective Analysis of the Effects of Perioperative Osteoanabolic Treatment on Patients With Spinal (Fusion) Surgery.","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2021-07-20","conditions":["Spinal (Fusion) Surgery"],"enrollment":40,"completionDate":"2022-11-01"},{"nctId":"NCT06258850","phase":"PHASE4","title":"REstoration of VItamin D in Pulmonary Arterial Hypertension","status":"NOT_YET_RECRUITING","sponsor":"Parc de Salut Mar","startDate":"2024-07-01","conditions":["Pulmonary Artery Hypertension","Vitamin d Deficiency"],"enrollment":102,"completionDate":"2027-12"},{"nctId":"NCT06096194","phase":"NA","title":"Vitamin D3-enhanced Eggs in Preschool Children","status":"COMPLETED","sponsor":"Instituto Nacional de Salud Publica, Mexico","startDate":"2018-07-15","conditions":["Vitamin D Deficiency","25-Hydroxyvitamin D3 Deficiency, Selective"],"enrollment":275,"completionDate":"2019-12-21"},{"nctId":"NCT03104855","phase":"PHASE1","title":"Clearance of 25-hydroxyvitamin D in Cystic Fibrosis","status":"COMPLETED","sponsor":"University of Washington","startDate":"2017-04-03","conditions":["Cystic Fibrosis"],"enrollment":10,"completionDate":"2023-09-06"},{"nctId":"NCT02548364","phase":"PHASE3","title":"Effect of Vitamin D on Ventricular Remodeling in Patients With Acute Myocardial Infarction (VITDAMI)","status":"COMPLETED","sponsor":"Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz","startDate":"2015-10","conditions":["Myocardial Infarction"],"enrollment":109,"completionDate":"2023-05"},{"nctId":"NCT05228925","phase":"","title":"GraviD-child Follow-up of the Children´s Health, Growth and Development Within the GraviD-study","status":"COMPLETED","sponsor":"Göteborg University","startDate":"2022-02-01","conditions":["Vitamin D Deficiency","Body Composition","Vascular Health","Cardiometabolic Risk"],"enrollment":172,"completionDate":"2023-02-14"},{"nctId":"NCT04735926","phase":"PHASE2,PHASE3","title":"Efficacy and Safety of Calcifediol vs Placebo in Subjects With Vitamin D Deficiency","status":"COMPLETED","sponsor":"Faes Farma, S.A.","startDate":"2020-12-23","conditions":["Vitamin D Deficiency","Vitamin D Insufficiency"],"enrollment":674,"completionDate":"2023-04-25"},{"nctId":"NCT05991778","phase":"","title":"Bioelectrical Impedance in Monitoring Hyperhydration and Polyneuromyopathy in Critically Ill Patients","status":"COMPLETED","sponsor":"University Hospital Ostrava","startDate":"2021-03-01","conditions":["Respiratory Distress Syndrome, Acute","Respiratory Insufficiency","Lung Ventilator","Hyperhydration","Hypoxemia","Chronic Obstructive Pulmonary Disease Exacerbation","Septic Shock"],"enrollment":61,"completionDate":"2022-05-31"},{"nctId":"NCT03008525","phase":"NA","title":"Vitamin D and Its Metabolites Quantification in Adipose Tissues of Obese and Non-obese Patients.","status":"RECRUITING","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2017-03-17","conditions":["Obesity; Endocrine"],"enrollment":60,"completionDate":"2026-09-13"},{"nctId":"NCT05860062","phase":"NA","title":"Vitamin D Supplementation in Episodic and Chronic Tension-type Headache","status":"UNKNOWN","sponsor":"Hospital de Especialidades, Centro Medico Nacional \"La Raza\", Instituto Mexicano del Seguro Social","startDate":"2023-04-18","conditions":["Chronic Tension-Type Headache"],"enrollment":20,"completionDate":"2023-12-20"},{"nctId":"NCT03403933","phase":"PHASE4","title":"Vitamin D Supplementation on in Major Orthopedic Surgery","status":"COMPLETED","sponsor":"I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio","startDate":"2017-01-16","conditions":["Hypovitaminosis D","Cardiovascular Diseases"],"enrollment":74,"completionDate":"2018-07-16"},{"nctId":"NCT05819918","phase":"","title":"Calcifediol in the Treatment of COVID 19","status":"COMPLETED","sponsor":"Maimónides Biomedical Research Institute of Córdoba","startDate":"2022-04-01","conditions":["COVID-19"],"enrollment":728,"completionDate":"2023-04-17"},{"nctId":"NCT05803681","phase":"NA","title":"CCEF in the Treatment of Acute VFFs: Randomized Controlled Trial","status":"COMPLETED","sponsor":"University of Bari Aldo Moro","startDate":"2015-01-01","conditions":["Vertebral Fracture","Osteoporotic Fractures"],"enrollment":70,"completionDate":"2020-12-31"},{"nctId":"NCT04156074","phase":"NA","title":"Innovative Food Structures to Enhance Nutrient Bioavailability","status":"COMPLETED","sponsor":"University College Dublin","startDate":"2019-11-04","conditions":["Vitamin D Deficiency","Aging Well"],"enrollment":80,"completionDate":"2021-12-31"},{"nctId":"NCT04366908","phase":"PHASE2","title":"Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome","status":"COMPLETED","sponsor":"Maimónides Biomedical Research Institute of Córdoba","startDate":"2020-05-07","conditions":["SARS-CoV 2","COVID19","SARS (Severe Acute Respiratory Syndrome)","Cytokine Release Syndrome","Cytokine Storm"],"enrollment":517,"completionDate":"2022-04-19"},{"nctId":"NCT03499327","phase":"NA","title":"Human Intervention Study to Increase 25-hydroxyvitamin D Levels","status":"COMPLETED","sponsor":"University of Jena","startDate":"2018-03-05","conditions":["Vitamin D3 Deficiency"],"enrollment":50,"completionDate":"2018-04-30"},{"nctId":"NCT04865432","phase":"NA","title":"Solius UV Light Source in Improving Serum Levels of 25-hydroxyvitamin D","status":"COMPLETED","sponsor":"Boston University","startDate":"2021-08-24","conditions":["Vitamin D Deficiency","Vitamin D Insufficiency"],"enrollment":10,"completionDate":"2021-12-12"},{"nctId":"NCT03588884","phase":"PHASE4","title":"Repeated-dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of CTAP101, Immediate-release Calcifediol, High-dose Cholecalciferol, and Paricalcitol Plus Low-dose Cholecalciferol in Patients With Secondary Hyperparathyroidism, Chronic Kidney Disease 3-4 and Vitamin D Insufficiency","status":"COMPLETED","sponsor":"OPKO Health, Inc.","startDate":"2018-06-08","conditions":["Secondary Hyperparathyroidism Due to Renal Causes","Vitamin D Insufficiency","CKD Stage 3","CKD Stage 4"],"enrollment":69,"completionDate":"2020-04-24"},{"nctId":"NCT02814591","phase":"","title":"Development of a Non-invasive Assessment of Human Bone Quality Using Spatially Offset Raman Spectroscopy","status":"UNKNOWN","sponsor":"University College, London","startDate":"2011-10","conditions":["Osteoarthritis","Osteoporosis","Osteogenesis Imperfecta","Rickets / Osteomalacia","Bone Infection"],"enrollment":245,"completionDate":"2025-06"},{"nctId":"NCT05613192","phase":"PHASE3","title":"Effectiveness of Inactive Vitamin D Supplementation in Non-Alcoholic Fatty Liver Disease Patients","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2022-10-31","conditions":["Non-Alcoholic Fatty Liver Disease"],"enrollment":100,"completionDate":"2023-03-05"},{"nctId":"NCT05343273","phase":"","title":"25-Hydroxyvitamin D Levels in Patients With Periodontitis (Stage III)","status":"COMPLETED","sponsor":"Ataturk University","startDate":"2022-03-10","conditions":["Vitamin D Deficiency","Periodontitis"],"enrollment":83,"completionDate":"2022-05-10"},{"nctId":"NCT03576716","phase":"PHASE1","title":"Clearance of 25-hydroxyvitamin D3 During Vitamin D3 Supplementation","status":"COMPLETED","sponsor":"University of Washington","startDate":"2018-06-01","conditions":["Chronic Kidney Disease"],"enrollment":19,"completionDate":"2021-01-01"},{"nctId":"NCT05340985","phase":"PHASE4","title":"Investigating the Effects of Hydroxyvitamin D3 on Multiple Sclerosis","status":"UNKNOWN","sponsor":"Tehran University of Medical Sciences","startDate":"2022-07","conditions":["Multiple Sclerosis, Relapsing-Remitting","Adult ALL","Vitamin D3 Deficiency"],"enrollment":54,"completionDate":"2023-12"},{"nctId":"NCT05306704","phase":"PHASE3","title":"High-Dose Vitamin D3 Supplementation in the Treatment of Human Immune Deficiency Virus Patients Trial","status":"COMPLETED","sponsor":"University of the Punjab","startDate":"2019-02-15","conditions":["HIV-1-infection","Hypovitaminosis D"],"enrollment":95,"completionDate":"2022-01-31"},{"nctId":"NCT04579640","phase":"PHASE3","title":"Trial of Vitamin D to Reduce Risk and Severity of COVID-19 and Other Acute Respiratory Infections","status":"COMPLETED","sponsor":"Queen Mary University of London","startDate":"2020-10-27","conditions":["Covid19","Acute Respiratory Tract Infection"],"enrollment":6200,"completionDate":"2022-02-28"},{"nctId":"NCT04174625","phase":"NA","title":"The Effect of Omega 3 on 25 Hydroxyvitamin D","status":"COMPLETED","sponsor":"Applied Science Private University","startDate":"2020-11-25","conditions":["25-hydroxyvitamin D Levels"],"enrollment":80,"completionDate":"2021-12-15"},{"nctId":"NCT04412694","phase":"PHASE4","title":"The Effect of Preoperative Oral Dexamethasone Supplementation on the Outcome of Thyroidectomised Patients.","status":"UNKNOWN","sponsor":"Medical University of Lodz","startDate":"2020-07-01","conditions":["Hypocalcemia","Vitamin D Deficiency","Postoperative Complications","Postoperative Nausea","Postoperative Pain","Voice Hoarseness","Hypoparathyroidism Postprocedural"],"enrollment":100,"completionDate":"2022-12"},{"nctId":"NCT05212519","phase":"","title":"Correlation of Vitamin D Levels in Early Pregnancy With Gestational Diabetes and Pregnancy Outcomes","status":"UNKNOWN","sponsor":"Min Shang","startDate":"2022-01-01","conditions":["GDM"],"enrollment":2000,"completionDate":"2024-01-01"},{"nctId":"NCT05137964","phase":"","title":"A Cross Sectional Evaluation of Vitamin D Status and Ovarian Reserve Markers","status":"COMPLETED","sponsor":"Australian Concept Medical Center","startDate":"2016-08-01","conditions":["Subfertility, Female"],"enrollment":199,"completionDate":"2021-07-01"},{"nctId":"NCT05067699","phase":"","title":"Vitamin D Level in Recurrent PV","status":"UNKNOWN","sponsor":"Kasr El Aini Hospital","startDate":"2021-09-01","conditions":["Recurrent Pityriasis Versicolor"],"enrollment":200,"completionDate":"2022-03-01"},{"nctId":"NCT04591847","phase":"PHASE3","title":"Pregnancy Outcome and Vitamin D Level Among Vitamin D Supplementation During Pregnancy","status":"COMPLETED","sponsor":"Department of Medical Services Ministry of Public Health of Thailand","startDate":"2020-10-19","conditions":["Pregnancy Outcome Among Vitamin D Supplementation During Pregnancy"],"enrollment":60,"completionDate":"2021-08-31"},{"nctId":"NCT05037253","phase":"PHASE4","title":"COVID-19 Morbidity in Healthcare Workers and Vitamin D Supplementation","status":"COMPLETED","sponsor":"Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health","startDate":"2020-10-30","conditions":["COVID-19 Respiratory Infection"],"enrollment":128,"completionDate":"2021-05-30"},{"nctId":"NCT02937350","phase":"PHASE1","title":"Clearance of 25-hydroxyvitamin D in Chronic Kidney Disease","status":"COMPLETED","sponsor":"University of Washington","startDate":"2017-03-01","conditions":["Chronic Kidney Disease"],"enrollment":88,"completionDate":"2021-01-01"},{"nctId":"NCT05018988","phase":"NA","title":"Vitamin D in School Children","status":"UNKNOWN","sponsor":"University of Ulster","startDate":"2019-11-01","conditions":["Vitamin D Deficiency","Musculoskeletal Diseases","Cognitive Delay, Mild"],"enrollment":118,"completionDate":"2025-10-30"},{"nctId":"NCT01262300","phase":"PHASE1","title":"Vitamin D Supplementation And Varicella Zoster Virus Vaccine Responsiveness In Older Long-Term Care Residents","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2010-11","conditions":["Immunosenescence","Shingles"],"enrollment":33,"completionDate":"2014-01-23"},{"nctId":"NCT04207294","phase":"NA","title":"Vitamin D Enriched Meat Project (Acute Study)","status":"COMPLETED","sponsor":"University of Ulster","startDate":"2020-01-16","conditions":["Vitamin D Deficiency"],"enrollment":15,"completionDate":"2020-04-10"},{"nctId":"NCT02091219","phase":"EARLY_PHASE1","title":"Effects of Vitamin D3 Versus 25OHD3 on Mineral Metabolism and Immune Function","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2014-06","conditions":["Vitamin D Deficiency"],"enrollment":35,"completionDate":"2019-12-07"},{"nctId":"NCT03898336","phase":"NA","title":"Eat2beNICE Vitamins and Nutrients as Supplementation for Impulsivity, Irritability, and Compulsivity","status":"UNKNOWN","sponsor":"Radboud University Medical Center","startDate":"2019-09-18","conditions":["Impulsive Behavior"],"enrollment":210,"completionDate":"2022-09-30"},{"nctId":"NCT02395081","phase":"NA","title":"Trial of Vitamin D Supplements to Raise Calcidiol Levels of Pregnant Women in Mongolia","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2015-02","conditions":["Pregnancy","Vitamin D Deficiency"],"enrollment":360,"completionDate":"2016-12"},{"nctId":"NCT03213886","phase":"PHASE4","title":"The Effect of Supplementation of Vitamin D Deficiency in Older People With Acute Hip Fracture:","status":"COMPLETED","sponsor":"Leonor Cuadra Llopart","startDate":"2018-01-01","conditions":["Hip Fracture","Vitamin D Deficiency"],"enrollment":50,"completionDate":"2020-07-30"},{"nctId":"NCT04637880","phase":"","title":"25- Hydroxyvitamin D Levels in Pregnancy and Effects on Pregnancy Related Disorders","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2012-07","conditions":["Vitamin d Deficiency","Preeclampsia","Preterm Delivery","Gestational Hypertension","Gestational Diabetes"],"enrollment":249,"completionDate":"2018-07-01"},{"nctId":"NCT04622982","phase":"NA","title":"A Multidisciplinary Intervention for Weight Loss","status":"COMPLETED","sponsor":"Azienda di Servizi alla Persona di Pavia","startDate":"2016-02-01","conditions":["Obesity"],"enrollment":151,"completionDate":"2020-09-30"},{"nctId":"NCT02185222","phase":"PHASE3","title":"Effect of Vitamin D on Cognitive Decline of Patients With Memory Complaint","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2014-10-23","conditions":["Memory Disorders","Age-Related Cognitive Decline"],"enrollment":68,"completionDate":"2018-10-10"},{"nctId":"NCT03334136","phase":"NA","title":"The Effect of Vitamin D Supplementation on Psoriasis Severity","status":"COMPLETED","sponsor":"University Hospital of North Norway","startDate":"2017-11-24","conditions":["Psoriasis","Vitamin D Deficiency"],"enrollment":115,"completionDate":"2019-05-13"},{"nctId":"NCT04443387","phase":"NA","title":"Vitamin D Regulates the Expression of Glucocorticoid Receptors in Blood of Severe Asthmatic Patients","status":"COMPLETED","sponsor":"Dubai Health Authority","startDate":"2012-04-01","conditions":["Effect of Drug"],"enrollment":45,"completionDate":"2014-12-31"},{"nctId":"NCT04386850","phase":"PHASE2,PHASE3","title":"Oral 25-hydroxyvitamin D3 and COVID-19","status":"UNKNOWN","sponsor":"Tehran University of Medical Sciences","startDate":"2020-04-14","conditions":["COVID 19"],"enrollment":1500,"completionDate":"2021-03-15"},{"nctId":"NCT03401541","phase":"EARLY_PHASE1","title":"25-Hydroxyvitamin D Pharmacokinetic Study","status":"COMPLETED","sponsor":"Boston University","startDate":"2018-10-01","conditions":["Vitamin D Deficiency","Fat Malabsorption"],"enrollment":16,"completionDate":"2019-11-01"},{"nctId":"NCT03644212","phase":"PHASE4","title":"Vitamin D Increases Serum Levels of the Soluble Receptor for Advanced Glycation End Products in Women With PCOS","status":"COMPLETED","sponsor":"Maimonides Medical Center","startDate":"2012-07","conditions":["Polycystic Ovary Syndrome","Vitamin D Deficiency"],"enrollment":79,"completionDate":"2013-10"},{"nctId":"NCT02168660","phase":"PHASE2","title":"Correction of Vitamin D Levels and Its Effect on Insulin Resistance and Weight Gain in Obese Youth","status":"COMPLETED","sponsor":"Perrin C White, MD","startDate":"2011-03","conditions":["Obesity","Insulin Resistance","Vitamin D Deficiency"],"enrollment":109,"completionDate":"2015-10-11"},{"nctId":"NCT04145492","phase":"PHASE2,PHASE3","title":"Effect of Vitamin K 2 on Vascular Calcification in Hemodialysis Patients","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2019-09-01","conditions":["End Stage Renal Disease"],"enrollment":60,"completionDate":"2020-02-01"},{"nctId":"NCT04133441","phase":"","title":"25-Hydroxyvitamin D Levels Are Negatively Associated With Platelets Number in a Cohort of Overweight and Obese Subjects","status":"COMPLETED","sponsor":"Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis","startDate":"2019-01-01","conditions":["Obesity"],"enrollment":341,"completionDate":"2019-09-01"},{"nctId":"NCT03660800","phase":"PHASE1","title":"Pharmacokinetics and Safety Study of CTAP101 Capsules in Japanese and Non-Japanese Healthy Subjects and Non-Japanese Healthy Subjects","status":"COMPLETED","sponsor":"OPKO Health, Inc.","startDate":"2018-08-20","conditions":["Vitamin D Insufficiency","Secondary Hyperparathyroidism"],"enrollment":67,"completionDate":"2019-01-22"},{"nctId":"NCT02274623","phase":"PHASE1","title":"Effect of CTAP101 Capsules on Ca/iPTH in Advanced Breast/Prostate Cancer Patients Treated With Denosumab/Zoledronic Acid","status":"COMPLETED","sponsor":"OPKO Health, Inc.","startDate":"2014-12","conditions":["Breast Cancer","Prostate Cancer","Bone Neoplasms","Hypocalcemia","Hyperparathyroidism, Secondary"],"enrollment":33,"completionDate":"2017-03-17"},{"nctId":"NCT02527668","phase":"PHASE2","title":"To Test the Effect of Calcifediol Hy.D Supplementation on Muscle Function and Bone Quality in Younger Postmenopausal Women With Osteopenia","status":"COMPLETED","sponsor":"dsm-firmenich Switzerland AG","startDate":"2015-09","conditions":["Osteopenia/Osteoporosis"],"enrollment":150,"completionDate":"2018-12"},{"nctId":"NCT02293187","phase":"NA","title":"Impact of Vitamin D on 25-hydroxyvitamin D Levels and Physical Function","status":"COMPLETED","sponsor":"Tufts University","startDate":"2015-03-23","conditions":["Vitamin D Deficiency","Sarcopenia"],"enrollment":100,"completionDate":"2018-12-31"},{"nctId":"NCT03871868","phase":"","title":"Vitamin D Levels And Myoma Uteri","status":"COMPLETED","sponsor":"Kanuni Sultan Suleyman Training and Research Hospital","startDate":"2018-12-01","conditions":["Myoma;Uterus","Vitamin D Deficiency","Polycystic Ovary"],"enrollment":300,"completionDate":"2019-03-01"},{"nctId":"NCT03820895","phase":"","title":"Vitamin D Levels in Adolescent Idiopathic Scoliosis","status":"COMPLETED","sponsor":"Security Forces Hospital","startDate":"2016-10-01","conditions":["Scoliosis Idiopathic","Vitamin D Deficiency","BMD"],"enrollment":60,"completionDate":"2019-01-10"},{"nctId":"NCT01939977","phase":"PHASE4","title":"Efficacy and Safety of Paricalcitol in the Reduction of Secondary Hyperparathyroidism After Kidney Transplantation.","status":"COMPLETED","sponsor":"Fundación Senefro","startDate":"2014-01","conditions":["Secondary Hyperparathyroidism Due to Renal Causes"],"enrollment":148,"completionDate":"2015-12"},{"nctId":"NCT03537027","phase":"PHASE1","title":"Efficiency of Vitamin D3 and 25-hydroxyvitamin D3 on Transcriptomic Changes of Low Vitamin D Responders","status":"COMPLETED","sponsor":"University of Eastern Finland","startDate":"2018-05-03","conditions":["Vitamin D Receptor Target Gene Expression","Serum 25(OH)D Concentration"],"enrollment":40,"completionDate":"2018-05-31"},{"nctId":"NCT03691896","phase":"PHASE3","title":"Calcium (ca),Phosphorus( P) and 25-hydroxyvitamin D(25OHD)] in Infants Born ≤ 32 PMA Gestational Weeks (GA)","status":"UNKNOWN","sponsor":"Centre of Postgraduate Medical Education","startDate":"2016-01","conditions":["Infant, Premature, Diseases"],"enrollment":200,"completionDate":"2019-12"},{"nctId":"NCT03584529","phase":"NA","title":"Association Between Vitamin D and the Development of Uterine Fibroids","status":"UNKNOWN","sponsor":"Second Affiliated Hospital of Wenzhou Medical University","startDate":"2018-09-15","conditions":["Gynaecological Disease","Vitamin D Deficiency"],"enrollment":360,"completionDate":"2021-07-01"},{"nctId":"NCT03496246","phase":"NA","title":"Vitamin D Status in Inflammatory Bowel Disease","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2018-04","conditions":["Vitamin D Deficiency","Inflammatory Bowel Diseases"],"enrollment":50,"completionDate":"2019-06"},{"nctId":"NCT01523496","phase":"PHASE2,PHASE3","title":"Vitamin D Supplementation in HIV Youth","status":"COMPLETED","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2011-12","conditions":["HIV Infections"],"enrollment":190,"completionDate":"2016-08"},{"nctId":"NCT03310242","phase":"NA","title":"Comparison of Sunlight Exposure and Vitamin D Supplementation on Serum 25-hydroxyvitamin D Levels","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2015-06-01","conditions":["Vitamin D Deficiency","Cardiometabolic Risk Factors"],"enrollment":150,"completionDate":"2015-11-30"},{"nctId":"NCT02750293","phase":"PHASE3","title":"The Effect of Vitamin D Supplementation on Cardiovascular Risk Factors","status":"COMPLETED","sponsor":"University of Tromso","startDate":"2015-06","conditions":["Vitamin D Deficiency"],"enrollment":411,"completionDate":"2017-09"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Capsule","formulations":[{"form":"CAPSULE, EXTENDED RELEASE","route":"ORAL","productName":"Rayaldee"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000020410","MMSL":"399","NDDF":"001016","UNII":"P6YZ13C99Q","VUID":"4022405","CHEBI":"CHEBI:17933","VANDF":"4021905","RXNORM":"1889","UMLSCUI":"C0006657","chemblId":"CHEMBL3544909","ChEMBL_ID":"CHEMBL1040","KEGG_DRUG":"D00122","DRUGBANK_ID":"DB00146","PUBCHEM_CID":"5283731","SNOMEDCT_US":"259337002","IUPHAR_LIGAND_ID":"6921","SECONDARY_CAS_RN":"63283-36-3","MESH_DESCRIPTOR_UI":"D002112"},"formularyStatus":[],"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"present","companyName":"Eirgen","relationship":"Current Owner"}],"pharmacokinetics":{"source":"FDA label","halfLife":"11 days"},"publicationCount":385,"therapeuticAreas":["Nephrology"],"atcClassification":{"source":"DrugCentral","atcCode":"A11CC06","allCodes":["A11CC06","H05BX05"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026","pmid":"41846928","title":"Vitamin D(3) as an immunomodulatory agent: molecular mechanisms, clinical translation, and precision therapeutic strategies.","journal":"Frontiers in immunology"},{"date":"2026 Mar 25","pmid":"41811220","title":"Structure-Guided Co-Evolution of Fungal Unspecific Peroxygenase for Improved VD(3) C25-Hydroxylation by Substrate-Binding Pocket Engineering.","journal":"Journal of agricultural and food chemistry"},{"date":"2024","pmid":"41695203","title":"Quantification of 25-hydroxyvitamin D (3) in dried blood spots as compared to plasma among Indian adults.","journal":"F1000Research"},{"date":"2025","pmid":"41608747","title":"Increase in testosterone and cortisol one week after repeated exercise in a cold environment.","journal":"Frontiers in physiology"},{"date":"2026 Jan 20","pmid":"41556264","title":"Synergistic Tuning of Conformational Dynamics, Electron Tunneling, and Substrate Positioning Enhances Electron Transfer in a P450 Chimera for Calcifediol Biosynthesis.","journal":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)"}],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"approved","companyName":"Eirgen","companyId":"","modality":"Small molecule","firstApprovalDate":"1980","enrichmentLevel":4,"visitCount":2,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2024-01-19T00:00:00.000Z","mah":"EIRGEN","brand_name_local":null,"application_number":"NDA208010"},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"patentsNormalised":[{"patent_number":"10213442","territory":"US","patent_type":"Formulation","expiry_date":"2027-02-02T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9943530","territory":"US","patent_type":"Method of Use","expiry_date":"2027-02-02T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8906410","territory":"US","patent_type":"Formulation","expiry_date":"2027-02-02T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8207149","territory":"US","patent_type":"Method of Use","expiry_date":"2028-04-25T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9498486","territory":"US","patent_type":"Method of Use","expiry_date":"2028-04-25T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8778373","territory":"US","patent_type":"Method of Use","expiry_date":"2028-04-25T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"11154509","territory":"US","patent_type":"Method of Use","expiry_date":"2028-04-25T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9408858","territory":"US","patent_type":"Method of Use","expiry_date":"2028-04-25T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9925147","territory":"US","patent_type":"Formulation","expiry_date":"2028-04-25T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8361488","territory":"US","patent_type":"Formulation","expiry_date":"2028-07-19T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8426391","territory":"US","patent_type":"Method of Use","expiry_date":"2028-08-27T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"11801253","territory":"US","patent_type":"Formulation","expiry_date":"2030-09-07T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"11253528","territory":"US","patent_type":"Formulation","expiry_date":"2034-03-14T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"10357502","territory":"US","patent_type":"Formulation","expiry_date":"2034-03-14T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"10300078","territory":"US","patent_type":"Formulation","expiry_date":"2034-03-14T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9861644","territory":"US","patent_type":"Formulation","expiry_date":"2034-03-14T00:00:00.000Z","status":"active","paragraph_iv_filed":false}],"trialStats":{"total":4,"withResults":3},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:01:10.652200+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}